SCHEMBL10200415

SCHEMBL10200415

Cc1cccc(-c2cc(O)c3c(O)c(CO)ccc3n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 7/20 0.38
KDM4E B2RXH2 5/20 0.38
LMNA P02545 4/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
IDO1 P14902 1/20 0.38
METAP2 P50579 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
XDH P47989 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10200411 0.86 MEN1 (0.40) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294625 0.85 ESRRB (0.39) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL15233227 0.84 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294630 0.81 KMT2A (0.37) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294623 0.80 ESR1 (0.43) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294626 0.78 GRM2 (0.36) MEN1KMT2AKDM4EMAPTNPC1
SCHEMBL15233228 0.77 ALDH1A1 (0.39) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294634 0.75 ALDH1A1 (0.42) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294619 0.71 MAPT (0.39) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL18294628 0.69 DHODH (0.43) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9717721-B2 Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry TAIRX, INC. (TW) 2017-08-01 US disclosed
US-20160354361-A1 NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY TAIRX INC. (TW) 2016-12-08 US disclosed
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Efficient Pharma Management Corporate (TW) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354361-A1 NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY TEK, FLT1, VHL MEN1 754/4885KMT2A 776/4885ALDH1A1 1091/4885
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES SLC22A8, ABCC8, CYP2C8 MEN1 2493/4885KMT2A 2015/4885ALDH1A1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.